Oren Pleniceanu

Oren Pleniceanu

Auto-generated profile, based on publicly available information

Oren Pleniceanu

Kidney Research Lab, Institute of Nephrology and Hypertension, Sheba Medical Center, Israel; Faculty of Medicine, Tel-Aviv University, Israel; Sheba Medical Center Physician-Scientist Program, Israel

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in Cell Reports
Verified
Journal Article
Open access
YRYuval Rinkevich
Yuval Rinkevich
DMDaniel T. Montoro
Daniel T. Montoro
HCHumberto Contreras-Trujillo
Humberto Contreras-Trujillo
OHOrit Harari-Steinberg
Orit Harari-Steinberg
ANAaron M. Newman
Aaron M. Newman
BDBenjamin Dekel
Benjamin Dekel
The mechanism and magnitude by which the mammalian kidney generates and maintains its proximal tubules, distal tubules, and collecting ducts remain controversial. Here, we use long-term in vivo genetic lineage tracing and clonal analysis of individual cells from kidneys undergoing development, maintenance, and regeneration. We show that the adult mammalian kidney undergoes continuous tubulogenesis via expansions of fate-restricted clones. Kidneys recovering from damage undergo tubulogenesis through expansions of clones with segment-specific borders, and renal spheres developing in vitro from individual cells maintain distinct, segment-specific fates. Analysis of mice derived by transfer of color-marked embryonic stem cells (ESCs) into uncolored blastocysts demonstrates that nephrons are polyclonal, developing from expansions of singly fated clones. Finally, we show that adult renal clones are derived from Wnt-responsive precursors, and their tracing in vivo generates tubules that are segment specific. Collectively, these analyses demonstrate that fate-restricted precursors functioning as unipotent progenitors continuously maintain and self-preserve the mouse kidney throughout life.

22 July 2010 in Stem Cells
Verified
Journal Article
Open access
PDF file
OPOren Pleniceanu
Oren Pleniceanu
OHOrit Harari-Steinberg
Orit Harari-Steinberg
BDBenjamin Dekel
Benjamin Dekel
End‐stage renal disease (ESRD) is defined as the inability of the kidneys to remove waste products and excess fluid from the blood. ESRD progresses from earlier stages of chronic kidney disease (CKD) and occurs when the glomerular filtration rate (GFR) is below 15 ml/minute/1.73 m2. CKD and ESRD are dramatically rising due to increasing aging population, population demographics, and the growing rate of diabetes and hypertension. Identification of multipotential stem/progenitor populations in mammalian tissues is important for therapeutic applications and for understanding developmental processes and tissue homeostasis. Progenitor populations are ideal targets for gene therapy, cell transplantation, and tissue engineering. The demand for kidney progenitors is increasing due to severe shortage of donor organs. Because dialysis and transplantation are currently the only successful therapies for ESRD, cell therapy offers an alternative approach for kidney diseases. However, this approach may be relevant only in earlier stages of CKD, when kidney function and histology are still preserved, allowing for the integration of cells and/or for their paracrine effects, but not when small and fibrotic end‐stage kidneys develop. Although blood‐ and bone marrow‐derived stem cells hold a therapeutic promise, they are devoid of nephrogenic potential, emphasizing the need to seek kidney stem cells beyond known extrarenal sources. Moreover, controversies regarding the existence of a true adult kidney stem cell highlight the importance of studying cell‐based therapies using pluripotent cells, progenitor cells from fetal kidney, or dedifferentiated/reprogrammed adult kidney cells. STEM CELLS 2010; 28:1649–1660.

1 November 2013 in The American Journal of Pathology
Verified
Journal Article
Closed access
EBElla Buzhor
Ella Buzhor
DODorit Omer
Dorit Omer
OHOrit Harari-Steinberg
Orit Harari-Steinberg
ZDZohar Dotan
Zohar Dotan
EVEinav Vax
Einav Vax
BDBenjamin Dekel
Benjamin Dekel

1 July 2014 in Stem Cell Reports
Verified
Journal Article
Open access
RSRachel Shukrun
Rachel Shukrun
NPNaomi Pode-Shakked
Naomi Pode-Shakked
OPOren Pleniceanu
Oren Pleniceanu
DODorit Omer
Dorit Omer
EVEinav Vax
Einav Vax
BDBenjamin Dekel
Benjamin Dekel
An open question remains in cancer stem cell (CSC) biology whether CSCs are by definition at the top of the differentiation hierarchy of the tumor. Wilms' tumor (WT), composed of blastema and differentiated renal elements resembling the nephrogenic zone of the developing kidney, is a valuable model for studying this question because early kidney differentiation is well characterized. WT neural cell adhesion molecule 1-positive (NCAM1(+)) aldehyde dehydrogenase 1-positive (ALDH1(+)) CSCs have been recently isolated and shown to harbor early renal progenitor traits. Herein, by generating pure blastema WT xenografts, composed solely of cells expressing the renal developmental markers SIX2 and NCAM1, we surprisingly show that sorted ALDH1(+) WT CSCs do not correspond to earliest renal stem cells. Rather, gene expression and proteomic comparative analyses disclose a cell type skewed more toward epithelial differentiation than the bulk of the blastema. Thus, WT CSCs are likely to dedifferentiate to propagate WT blastema.

29 March 2016 in Scientific Reports
Verified
Journal Article
Open access
NSNaomi Pode Shakked
Naomi Pode Shakked
OPOren Pleniceanu
Oren Pleniceanu
RGRotem Gershon
Rotem Gershon
RSRachel Shukrun
Rachel Shukrun
IKItamar Kanter
Itamar Kanter
BDBenjamin Dekel
Benjamin Dekel
When assembling a nephron during development a multipotent stem cell pool becomes restricted as differentiation ensues. A faulty differentiation arrest in this process leads to transformation and initiation of a Wilms’ tumor. Mapping these transitions with respective surface markers affords accessibility to specific cell subpopulations. NCAM1 and CD133 have been previously suggested to mark human renal progenitor populations. Herein, using cell sorting, RNA sequencing, in vitro studies with serum-free media and in vivo xenotransplantation we demonstrate a sequential map that links human kidney development and tumorigenesis; In nephrogenesis, NCAM1+CD133− marks SIX2+ multipotent renal stem cells transiting to NCAM1+CD133+ differentiating segment-specific SIX2− epithelial progenitors and NCAM1−CD133+ differentiated nephron cells. In tumorigenesis, NCAM1+CD133− marks SIX2+ blastema that includes the ALDH1+ WT cancer stem/initiating cells, while NCAM1+CD133+ and NCAM1−CD133+ specifying early and late epithelial differentiation, are severely restricted in tumor initiation capacity and tumor self-renewal. Thus, negative selection for CD133 is required for defining NCAM1+ nephron stem cells in normal and malignant nephrogenesis.

1 September 2021 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
DODorit Omer
Dorit Omer
OPOren Pleniceanu
Oren Pleniceanu
YGYehudit Gnatek
Yehudit Gnatek
MNMichael Namestnikov
Michael Namestnikov
OCOsnat Cohen-Zontag
Osnat Cohen-Zontag
BDBenjamin Dekel
Benjamin Dekel
Significance Statement: Coronavirus disease 2019 (COVID-19) commonly results in AKI, but it is unknown whether AKI in patients with COVID-19 stems from direct kidney infection or indirect mechanisms. The authors explored the effects of infection with the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), both in monolayers of primary human kidney cells and in kidney spheroids, a three-dimensional model recapitulating human kidneys in cell composition and function. They demonstrated that the virus effectively infects and replicates in human tubular epithelial cells, but does not cause cytopathic effects. They also provide molecular evidence that activation of a type 1 IFN response may be the underlying mechanism of resistance to SARS-CoV-2–related cytopathic damage. In all, the findings indicate minimal—if any—direct tubular damage by SARS-CoV-2. Background: Although coronavirus disease 2019 (COVID-19) causes significan t morbidity, mainly from pulmonary involvement, extrapulmonary symptoms are also major componen ts of the disease. Kidney disease, usually presenting as AKI, is particularly severe among patients with COVID-19. It is unknown, however, whether such injury results from direct kidney infection with COVID-19’s causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or from indirect mechanisms. Methods: Using ex vivo cell models, we sought to analyze SARS-CoV-2 interactions with kidney tubular cells and assess direct tubular injury. These models comprised primary human kidney epithelial cells (derived from nephrectomies) and grown as either proliferating monolayers or quiescent three-dimensional kidney spheroids. Results: We demonstrated that viral entry molecules and high baseline levels of type 1 IFN–related molecules were present in monolayers and kidney spheroids. Although both models support viral infection and replication, they did not exhibit a cytopathic effect and cell death, outcomes that were strongly present in SARS-CoV-2–infected controls (African green monkey kidney clone E6 [Vero E6] cultures). A comparison of monolayer and spheroid cultures demonstrated higher infectivity and replication of SARS-CoV-2 in actively proliferating monolayers, although the spheroid cultures exhibited high er levels of ACE2. Monolayers exhibited elevation of some tubular injury molecules—including molecules related to fibrosis (COL1A1 and STAT6) and dedifferentiation (SNAI2)—and a loss of cell identity, evident by reduction in megalin (LRP2). The three-dimensional spheroids were less prone to such injury. Conclusions: SARS-CoV-2 can infect kidney cells without a cytopathic effect. AKI-induced cellular proliferation may potentially intensify infectivity and tubular damage by SARS-CoV-2, suggesting that early intervention in AKI is warranted to help minimize kidney infection.